Consolidated Investment Group LLC raised its position in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 85.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,000 shares of the pharmacy operator's stock after acquiring an additional 18,000 shares during the period. Consolidated Investment Group LLC's holdings in CVS Health were worth $3,342,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Kestra Investment Management LLC raised its position in shares of CVS Health by 7.2% during the 3rd quarter. Kestra Investment Management LLC now owns 4,123 shares of the pharmacy operator's stock valued at $353,000 after buying an additional 278 shares in the last quarter. Leuthold Group LLC grew its position in CVS Health by 9.8% in the third quarter. Leuthold Group LLC now owns 45,227 shares of the pharmacy operator's stock worth $3,876,000 after acquiring an additional 4,038 shares in the last quarter. Fulcrum Asset Management LLP increased its stake in CVS Health by 334.1% during the third quarter. Fulcrum Asset Management LLP now owns 26,043 shares of the pharmacy operator's stock worth $2,268,000 after acquiring an additional 20,044 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in CVS Health by 10.5% during the third quarter. Allspring Global Investments Holdings LLC now owns 178,522 shares of the pharmacy operator's stock valued at $15,210,000 after purchasing an additional 16,991 shares during the period. Finally, Missouri Trust & Investment Co raised its position in CVS Health by 6.7% during the third quarter. Missouri Trust & Investment Co now owns 32,701 shares of the pharmacy operator's stock valued at $2,802,000 after purchasing an additional 2,045 shares during the period. 80.66% of the stock is currently owned by institutional investors.
Insider Activity
In related news, EVP Prem Shah bought 23,855 shares of the stock in a transaction dated Friday, November 6th. The stock was purchased at an average cost of $83.89 per share, with a total value of $2,001,195.95. Following the completion of the purchase, the executive vice president owned 88,516 shares of the company's stock, valued at $7,425,607.24. This trade represents a 36.89% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.85% of the company's stock.
Key CVS Health News
Here are the key news stories impacting CVS Health this week:
- Positive Sentiment: An executive bought about $2 million of CVS stock, a notable insider purchase that may signal confidence in the company’s outlook. Insider Buying: CVS Health EVP Buys $2,001,195.95 in Stock
- Positive Sentiment: CVS’s latest quarter beat analyst estimates for earnings and revenue. Management cited pharmacy strength, progress in Medicare margin recovery, improvement in its medical benefit ratio and solid cash generation—supportive signs for its operating outlook. The top 5 analyst questions from CVS Health’s Q3 2026 earnings call
- Neutral Sentiment: CVS’s planned separation into two entities is being framed as potentially beneficial to shareholders, but Mark Cuban argued it would do little for patients and called for legislation targeting healthcare monopolies. The breakup’s financial benefits remain a key investor question. Mark Cuban on the CVS breakup
- Neutral Sentiment: A reported $2.1 million settlement is small relative to CVS’s scale, so its direct financial impact appears limited. CVS settlement will see $2.1 million paid out
- Negative Sentiment: CVS is challenging Tennessee’s law barring pharmacies from owning pharmacy benefit managers. The dispute adds regulatory uncertainty around its integrated business model, even as the company says pharmacy services will continue uninterrupted. CVS Health challenges Tennessee PBM ownership ban in federal court
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on CVS shares. Piper Sandler set a $112.00 target price on CVS Health in a research report on Wednesday, September 9th. Weiss Ratings cut shares of CVS Health from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Friday, October 9th. Argus increased their target price on shares of CVS Health from $104.00 to $114.00 and gave the company a "buy" rating in a research note on Wednesday, August 19th. Wells Fargo & Company raised their target price on shares of CVS Health from $103.00 to $123.00 and gave the stock an "overweight" rating in a report on Monday, July 13th. Finally, UBS Group dropped their price target on shares of CVS Health from $118.00 to $107.00 and set a "buy" rating for the company in a research note on Thursday, November 5th. Twenty-two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, CVS Health currently has a consensus rating of "Moderate Buy" and an average price target of $108.25.
View Our Latest Report on CVS
CVS Health Price Performance
Shares of CVS stock opened at $85.16 on Tuesday. CVS Health Corporation has a 52-week low of $69.51 and a 52-week high of $110.68. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.66 and a current ratio of 0.85. The firm has a market capitalization of $108.92 billion, a P/E ratio of 9.60, a P/E/G ratio of 0.73 and a beta of 0.58. The stock has a 50 day moving average price of $90.21 and a 200 day moving average price of $88.91.
CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The pharmacy operator reported $2.09 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.65 by $0.44. The company had revenue of $108.40 billion during the quarter, compared to analysts' expectations of $104.72 billion. CVS Health had a return on equity of 13.65% and a net margin of 2.62%. CVS Health's revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.60 EPS. As a group, sell-side analysts predict that CVS Health Corporation will post 8.25 earnings per share for the current year.
CVS Health Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Thursday, October 22nd were paid a dividend of $0.6650 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date of this dividend was Thursday, October 22nd. CVS Health's payout ratio is currently 30.97%.
About CVS Health
(
Free Report)
CVS Health is a U.S.-based health care company that operates retail pharmacies, provides pharmacy benefit management services, and offers health insurance and other health services. Its businesses include CVS Pharmacy, pharmacy benefit manager CVS Caremark, and Aetna, its health benefits division.
The company also provides care through MinuteClinic walk-in clinics and health care businesses including Oak Street Health and Signify Health. Its services span prescription fulfillment, pharmacy benefit management, health insurance, primary care, and in-home and community-based care.
Founded in 1963 as Consumer Value Stores in Lowell, Massachusetts, the company expanded from a retail pharmacy business into a broad health care organization and adopted the CVS Health name in 2014.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
